74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Kymera Therapeutics Inc
Closed
SectorHealthcare
33.46 8.81
Overview
Share price change
24h
Min
30.5
Max
33.65
Income | -8.3M -71M |
|---|---|
Sales | 3.7M 7.4M |
EPS | -0.89 |
Profit margin | -956.884 |
Employees | 188 |
EBITDA | -8.3M -69M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +80.98% upside |
Next Earnings | 9 May 2025 |
|---|
Market Cap | -523M 1.8B |
|---|---|
Previous open | 24.65 |
Previous close | 33.46 |
Technical Score
By Trading Central
Confidence
Very Strong Bullish Evidence
Kymera Therapeutics Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Kymera Therapeutics Inc Forecast
Price Target
By TipRanks
80.98% upside
12 Months Forecast
Average 55.56 USD 80.98%
High 72 USD
Low 49 USD
Based on 11 Wall Street analysts offering 12 month price targets forKymera Therapeutics Inc - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Kymera Therapeutics Inc
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
